-+ 0.00%
-+ 0.00%
-+ 0.00%

Biodexa Pharmaceuticals Announces University of Bonn, Germany Screening Participants For Phase 3 Serenta Study Evaluating eRapa In Familial Adenomatous Polyposis

Benzinga·11/24/2025 13:33:52
Listen to the news

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) announced today that the University of Bonn, Germany is now actively screening patients for the Phase 3 Serenta clinical trial evaluating eRapa in familial adenomatous polyposis (FAP). This marks the first European site activation for the registrational Serenta trial, representing a major milestone in expanding FAP treatment options to European patients who currently have no approved non-surgical therapeutic alternatives.